Additional information
| Trade Name | VOTRIENT 200 |
|---|---|
| Generic Name | Pazopanib |
| Manufacturer | Novartis India Ltd |
| Drug Type | Oncology |
| Indication | Kidney Cancer |
| Doasage Form | Tablet |
| Packaging | 1 X 30 Tablets 200mg |
| Strength | 200mg, 400mg |
VOTRIENT (Pazopanib)
₹1.00 – ₹2.00
Votrient Tablet is a protein kinase inhibitor which work by preventing the activity of proteins that are involved in the growth and spread of cancer cells.
Used in the treatment of kidney cancer (Renal cell carcinoma -RCC) and Soft-tissue sarcoma (STS), it is indicated in adults for the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease & is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
